Dr. David Bartlett | Allegheny Health Network | United States
Dr. David L. Bartlett is a distinguished surgical oncologist and cancer researcher specializing in innovative cancer treatments. 🎗️ He earned his M.D. from the University of Texas Medical School at Houston and completed his residency at the Hospital of the University of Pennsylvania. 🏥 He further honed his expertise through fellowships at Memorial Sloan Kettering Cancer Center. Dr. Bartlett has held prestigious leadership roles at the National Cancer Institute, University of Pittsburgh, and Allegheny Health Network, where he currently serves as System Chair of the AHN Cancer Institute. His contributions to surgical oncology and cancer research have shaped modern treatment approaches. 🔬
Professional Profile:
ORCID
Suitability for Best Researcher Award
Dr. David L. Bartlett is an exceptional candidate for the Best Researcher Award due to his groundbreaking contributions to surgical oncology and cancer research. His extensive experience in oncologic surgery, innovative treatment methods, and leadership in major cancer institutions sets him apart as a leading figure in the field. His work has significantly advanced cancer treatment strategies, improving patient outcomes and shaping the future of oncology.
Education & Experience 🎓📜
- B.A. – Rice University, Houston, Texas (1983) 🎓
- M.D. – University of Texas Medical School at Houston (1987) 🩺
- Residency – Surgery, Hospital of the University of Pennsylvania (1987-1993) 🏥
- Fellowship – Surgical Oncology, Memorial Sloan Kettering Cancer Center (1993-1995) 🔬
- Special Expert – Surgery Branch, National Cancer Institute (1995-1996) 🧬
- Senior Investigator – National Cancer Institute (1996-2001) 🏥
- Associate Professor – University of Pittsburgh (2001-2005) 📚
- Chief, Surgical Oncology – University of Pittsburgh (2001-2011) 🏥
- Bernard Fisher Endowed Professor of Surgery – University of Pittsburgh (2006-2020) 🎖️
- System Chair – AHN Cancer Institute (2020-present) 🌍
Professional Development & Leadership 🏆
Dr. Bartlett has significantly advanced surgical oncology through leadership roles and contributions to professional societies. 🎗️ He has been actively involved in the Society of Surgical Oncology (SSO), serving as Vice President, President-Elect, and President. 🎖️ His work includes chairing the UPMC Robotic Oversight Committee, leading the Regional Cancer Therapies Annual Meeting, and contributing to the FDA’s Cellular, Tissues, and Gene Therapies Advisory Committee. 🏥 As an editorial board member for journals like Cancer Gene Therapy and Clinical Colorectal Cancer, he has influenced research directions. Currently, as System Chair of the AHN Cancer Institute, he continues to pioneer cancer treatment advancements. 🔬
Research Focus 🔍
Dr. Bartlett specializes in cancer immunotherapy, regional cancer therapies, and surgical oncology. 🎗️ His research explores gene and cellular therapies, hyperthermic intraperitoneal chemotherapy (HIPEC), and regional perfusion techniques to enhance cancer treatment. 🔬 His NIH-funded studies have led to groundbreaking approaches in treating peritoneal and advanced-stage malignancies. 🧬 He has played a key role in integrating robotics and precision medicine into oncological surgery. 🤖 His focus on personalized cancer treatments continues to impact global oncology practices. 🌍 Through his work, he has significantly improved patient outcomes and contributed to the evolution of cancer surgery. 🏥
Awards & Honors 🏅
- Bernard Fisher Endowed Professor of Surgery – University of Pittsburgh (2006-2020) 🎖️
- President – Society of Surgical Oncology (2019-2020) 🏆
- Vice President – Society of Surgical Oncology (2017-2018) 🎗️
- Editorial Board Member – Cancer Gene Therapy, Annals of Surgical Oncology 📖
- Chair – UPMC Robotic Oversight Committee (2010-2014) 🤖
- Treasurer – Society of Surgical Oncology (2014-2017) 💰
- Board of Directors – James Ewing Foundation (2011-2018) 🏥
- FDA Advisory Committee Member – Cellular, Tissues, and Gene Therapies (2014-present) 🧬
Publication Top Notes:
-
🧫 Intra-Tumoral CD8+:CD3+ Lymphocyte Density Ratio in Appendix Cancer Is a Tumor Volume- and Grade-Independent Predictor of Survival (2025) – Cancers 🏥
-
👁️ Precision in Tear Fluid Biomarker Discovery: Quantitative Proteomic Profiling of Small-Volume, Individual Samples Using Capillary Tube Collection (2025) – Biomedicines 🧪
-
🦠 Fecal Microbiome Composition Correlates with Pathologic Complete Response in Patients with Operable Esophageal Cancer Treated with Combined Chemoradiotherapy and Immunotherapy (2024) – Cancers 💊
-
🏥 Assessing the Long-Term Priorities of Pancreaticoduodenectomy Survivors (2024) – HPB ❤️
-
🧬 Intratumoral Delivery of Interleukin 9 via Oncolytic Vaccinia Virus Elicits Potent Antitumor Effects in Tumor Models (2024) –Cancer🔬